The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia

• Published in: Neuropsychiatric disease and treatment Vol. 15; pp. 1045 - 1060
• Main Authors: Pietrini, Francesco, Albert, Umberto, Ballerini, Andrea, Calò, Paola, Maina, Giuseppe, Pinna, Federica, Vaggi, Marco, Boggian, Ileana, Fontana, Maria, Moro, Cesare, Carpiniello, Bernardo
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2019; Taylor & Francis Ltd; Dove; Dove Medical Press
• Subjects: Antipsychotic agents; Antipsychotics; Caregivers; Disabilities; Diseases; Drug therapy; Expert Opinion; Medical personnel; Mental health; Nurses; Patient care; Patient compliance; Patient-centered care; Patients; Psychiatrists; Psychologists; Quality of life; Recovery; Recovery (Medical); Schizophrenia; Second-generation long-acting injectable antipsychotics; Social workers; Workers; Morocco; antipsychotic; recovery; schizophrenia; quality of life; long-acting injections; subjective well-being
• ISSN: 1176-6328; 1178-2021; 1178-2021
• DOI: 10.2147/NDT.S199048

Schizophrenia is a chronic syndrome involving different clinical dimensions, and causes significant disability with a negative impact on the quality of life of patients and their caregivers. Current guidelines for the treatment of schizophrenia focus on maximizing a patient's adaptive functioning and quality of life in a recovery-oriented approach that encourages active collaboration among patients, caregivers, and mental health professionals to design and manage a customized and comprehensive care plan. In the present study, a panel of experts (psychiatrists, psychologists, nurse, and social worker) gathered to review and explore the need for contemporary use of second-generation antipsychotic long-acting injectables (SGA LAIs) in "recovery-oriented" and "patient-centered" care of schizophrenia. Starting from the available data and from sharing personal attitudes and experiences, the panel selected three clinical dimensions considered useful in characterizing each patient: phase of disease, adherence to treatment, and level of functioning. For each clinical dimension, perspectives of patients and caregivers with regard to needs, expectations, and personal experiences were reviewed and the role of SGA LAIs in achieving shared goals examined. The experts concluded that from today's modern perspectives, SGA-LAIs may play an important role in breaking the spiral of desocialization and functional decline in schizophrenia, thus favoring the recovery process.